SecBot SecBot
SECBOTREPLAY Home › Report › ARTV

ARTV · Artiva Biotherapeutics reported its full-year 2025 financial results,…

Artiva Biotherapeutics, Inc. · PRESS-RELEASE filed Mar 10, 2026 at 16:05 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Mar 10, 2026 at 16:05 ET

Artiva Biotherapeutics reported its full-year 2025 financial results, highlighting a net loss of $83.9 million, increased R&D spending, and a strong cash position of $108.0 million that funds operations into Q2 2027. The company emphasized clinical progress with AlloNK in refractory rheumatoid arthritis, including FDA Fast Track designation and upcoming data readouts in H1 2026, but reported zero revenue for the year.

  • Net loss was $83.9 million in 2025 vs. $65.4 million in 2024
  • Cash, cash equivalents, and investments totaled $108.0 million as of December 31, 2025, down from $185.4 million in 2024
  • Cash runway extends into Q2 2027
  • License and development support revenue was $0 in 2025 vs. $0.3 million in 2024

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access